関連する実験動画
Updated: Sep 9, 2025

08:15
Gastrointestinal Motility Monitor GIMM
Published on: December 1, 2010
31.0K
セロトニン6型受容体の逆アゴニストと中性アンタゴニストは排便を阻害する:腸の運動障害への関連性
Maciej Salaga1, Agata Binienda1, Vittorio Canale2
1Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.
European journal of pharmacology
|August 30, 2025
まとめ
活性状態と静止状態の両方でセロトニン5HT6受容体を遮断すると,マウスの腸の運動性と下痢が減少しました. これらの状態を標的とした特定の薬剤を組み合わせることで, 5-HT6受容体が潜在的な治療標的として強調され,最も顕著な効果が示されました.
科学分野:
- 神経胃腸内科
- 薬理学について
背景:
- セロトニン系,特にセロトニン5HT6受容体は,胃腸 (GI) の運動性と内臓の痛みに影響します.
- 刺激性腸症候群 (IBS) は,しばしば消化器機能の変化と痛みに関連しており,セロトニン系の役割を示唆しています.
研究 の 目的:
- セロトニン5HT6受容体の異なる構成状態を阻害することで腸の運動性と下痢に及ぼす影響を調査する.
- 機能的消化器疾患における構成活性およびアゴニスト活性化5-HT6受容体を標的とした治療の可能性を評価する.
主な方法:
- 全逆アゴニスト (SB- 39985) と部分逆アゴニスト (PZ- 14444) と中性逆アゴニスト (CPPQ) を腹膜内投与した.
- 腸の運動性を測定するために,これらの化合物の個々のおよび組み合わせによる排泄への影響を評価した.
- 薬剤の組み合わせによる受容体阻害の強化効果を研究した.
主要な成果:
- 逆アゴニストと中性アンタゴニストの両方が,生理学的およびストレス条件下で排泄を減少させた.
- 部分逆agonist PZ-1444の効果は,SB-399885またはCPPQと併用されたときに強化されました.
- PZ-1444とCPPQの組み合わせは,腸の運動を強く抑制することを示す,排便の最も顕著な減少を示した.
結論:
- 構成的に活発なセロトニン5HT6受容体と,アゴニストによって刺激されるセロトニン5HT6受容体は,腸の運動性と下痢に寄与する.
- セロトニン5HT6受容体を標的として,特にその構成状態の結合ブロックによって,IBSのような機能的消化器疾患に対する有望な治療戦略を提供します.
関連する概念動画
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
395
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
395
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
593
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
593
Drugs for Treatment of Diarrhea-Predominant IBS
292
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
292
Antidepressant Drugs: MAOIs and Other Agents
340
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
340
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
563
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
563
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
323
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
323

